Merck Expects 2024 Sales Of $63.4B-$64.4B Compared To Prior Guidance Of $63.1B-$64.3B And Consensus Of $64.341B
Portfolio Pulse from Benzinga Newsdesk
Merck has updated its full-year 2024 financial outlook, expecting sales between $63.4 billion and $64.4 billion, slightly higher than prior guidance. However, non-GAAP EPS is revised down to $7.94-$8.04 from $8.53-$8.65.
July 30, 2024 | 10:33 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Merck has updated its 2024 financial outlook with slightly higher sales expectations but lower non-GAAP EPS. This mixed update may lead to short-term volatility in the stock price.
The slight increase in sales guidance is positive, but the significant reduction in non-GAAP EPS could concern investors. This mixed outlook may result in short-term volatility for Merck's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100